Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333788 · ClinicalTrials.gov registry record · Phase 3
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 233
- Enrollment target
NCT00333788 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 233 participants.
The verdict
NCT00333788, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 233 participants
- Enrollment target
Study Summary
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 \[NCT00308581\]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.
Interventions
- BIOLOGICAL Certolizumab pegol (CDP870)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333788
The ClinicalTrials.gov registry entry for NCT00333788 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab pegol (CDP870) is the first listed.
NCT00333788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333788 about?
NCT00333788 is a clinical study titled "Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease". The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 \[NCT00308581\]. It will also assess the effect of subcutaneous CDP870 400 mg on direct cost parameters.
What is the current status of trial NCT00333788?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2006-10. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00333788?
The interventions under investigation include: Certolizumab pegol (CDP870) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00333788?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.